Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial)
Key facts
- Who runs it
- University Health Network, Toronto
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 120 people, planned
- Started
- 3 Nov 2025
- Expected to end
- 30 Apr 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- H5N1 vaccine (Arepanrix, GSK)
- Placebo
- Record updated
- 23 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Age ≥ 18 and greater than 3 months post-transplant
- Stable graft function
- eGFR >30mL/min/1.73m2
- Able to provide informed consent
Who cannot take part
- Previous life-threatening reaction to influenza vaccine (ie Guillain Barré Syndrome)
- Ongoing or recent therapy for acute rejection (within the previous 30 days)
- Receiving treatment for active or acute infection
- Allergy to vaccine components
- Ongoing active cytomegalovirus (CMV) infection with viral load of greater or equal to 1000 international units/ml in the last 7 days
- Febrile illness in the past 2 weeks
- Diagnosis of influenza virus infection in the last 90 days
- Rituximab in the last 6 months
- Unable to provide informed consent
- 2025 seasonal influenza vaccination in preceding 6 weeks
- Recent other vaccination in last 14 days
- Receipt of intravenous immunoglobulin in last 30 days or expected to receive in next 30 days; Life expectancy < 3 months
- Pregnancy known at the time of enrolment
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Influenza is an important pathogen in transplant recipients. The current widespread outbreak of highly pathogenic H5N1 avian influenza (HPAI) in livestock, and the occurrence of several human cases of infection suggest that the next influenza pandemic may be soon approaching. Transplant patients will likely be uniquely predisposed to serious infection with high morbidity and mortality. There are a number of important reasons that evaluation of prevention strategies are critical in this highly vulnerable population. Currently, there is no data on the immunogenicity of H5Nx vaccines in this highly vulnerable population. The investigators plan to study the safety and immunogenicity of a two-dose regimen of the pandemic influenza H5N1 vaccine in organ transplant patients.
The 2 groups in the trial
- H5N1 vaccineExisting treatment, for comparison
This arm will receive 2 doses of approved H5N1 vaccine, 3 weeks apart
Treatment: H5N1 vaccine (Arepanrix, GSK)
- PlaceboPlacebo, for comparison
This arm will receive 2 doses of normal saline (placebo), 3 weeks apart
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial): Safety and Immunogenicity of Pandemic Influenza Vaccine in Organ Transplant Recipients
- Record updated
- 23 October 2026